Three‐months optical coherence tomography analysis of a biodegradable polymer, sirolimus‐eluting stent

Kretov, Еvgeny; Нарышкин, И А; Baystrukov, V. I.; Grazhdankin, Igor; Prokhorikhin, Aleksei; Зубарев, Д. Д.; Biryukov, Alexey; Верин, В. В.; Boykov, A. A.; Малаев, Д. У.; Pokushalov, Evgeny; Romanov, Alexander; Bergmann, Martin

doi:10.1111/joic.12510

Cited by 9 publications

(10 citation statements)

References 23 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…На различных моделях животных и в клинических исследованиях [39][40][41] было продемонстрировано, что СЛП с сиролимусом уменьшает утолщение неоинтимы по сравнению с ГМС и стентами, покрытыми полимерами. При этом происходит раннее эффективное созревание клеток неоэндотелия [42,43], на 25% снижается риск тромбоза стента по сравнению с другими СЛП нового поколения [44].…”

Section: развитие технологии коронарного стентированияunclassified

Coronary stent technology and the role of inflammation in the atherogenesis: problems and prospects

et al. 2021

View full text Add to dashboard Cite

Обзоры и лекции или фиброзом, что привело бы к разработке специфической терапии, направленной на подавление провоспалительных медиаторов и защиту сердца от воспалительного повреждения.Ключевые слова: ишемическая болезнь сердца, чрескожное коронарное вмешательство, воспаление, эндотоксин, цитокины, системная эндотоксинемия. Конфликт интересов. Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.Источник финансирования. Авторы заявляют об отсутствии финансирования при написании статьи.

show abstract

Section: развитие технологии коронарного стентированияunclassified

Coronary stent technology and the role of inflammation in the atherogenesis: problems and prospects

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The technological advances of R-onyx DES provide the unmet needs of intracranial stenting, and the thin strut thickness remains a crucial characteristic in stent platform, demonstrating better device conformability, easier navigability, and lesser strut malapposition. Also, thin struts are associated with low levels of inflammation at the lesion site resulting in rapid and almost complete arterial re-endothelialization and reduced neointimal growth (29). Furthermore, the slim 2-mm stent enables stenting of a small target vessel diameter which is associated with a high incidence of vessel injury, difficult accessibility, and higher rates of ISR.…”

Section: -Month Angiogram (9 Patients)mentioning

confidence: 99%

Initial Experience With the Next-Generation Resolute Onyx Zotarolimus-Eluting Stent in Symptomatic Intracranial Atherosclerotic Disease

et al. 2020

View full text Add to dashboard Cite

Background and Purpose: Intracranial atherosclerotic disease (ICAD) is a common cause of stroke worldwide. Although there are different endovascular options for the treatment of symptomatic ICAD (sICAD), it is still controversial. Herein, we aim to study the safety and efficacy of a new generation of drug-eluting balloon-mounted stent (DES); Resolute (R) onyx DES in the treatment of sICAD. Methods: A prospectively maintained neuroendovascular procedures database in a high-volume comprehensive stroke center was reviewed from October 2019 through January 2020. Patients were included if they had sICAD (≥70% stenosis), failed medical management, and underwent intracranial stenting with R-onyx DES. Technical success was defined as the ability to deploy the device at the desired location and achievement of <30% residual stenosis. The primary outcome was the occurrence of complications within 72 h of the procedure (strokes, ischemic or hemorrhagic; and mortality). Secondary outcomes included rates of symptomatic and angiographic recurrence within 6 months of the procedure. Results: A total of 18 consecutive patients (mean age, 66.6 years; 44.4% were females and 94.4% were Hispanic) were eligible for the analysis. Indication for treatment was recurrent strokes in 13 and recurrent transient ischemic attack (TIA) in 5. A total of 22 symptomatic lesions with a mean baseline stenosis percent (84.9 ± 9.6) were treated using 23 R-onyx DES in 19 procedures. All procedures were done under general anesthesia with 100% technical success, and no reported periprocedural strokes or death. Among 13 patients who had clinical follow-up, 1 (7.7%) patient had TIA. There were no reported ischemic or hemorrhagic strokes. Angiographic follow-up for 9 (50%) patients showed no in-stent restenosis. Hassan et al. R-onyx DES in Treatment of sICAD Conclusion: The use of R-onyx DES in the treatment of sICAD is safe with high technical success rates. Large prospective multicenter trials with long-term follow-up are warranted.

show abstract

“…In the most recent European randomized trials, this stent demonstrated a very good safety and efficacy profile. Indeed, its low rate of stent thrombosis reached the non-inferiority statistical significance compared to Xience Prime stent (Abbott Inc., United States)[ 18 - 19 ] with a faster strut endothelium coverage evaluated by optical coherence tomography in respect to the competitors[ 20 ]. These results could be achieved even after overcoming the major intrinsic structural limitation to the stent’s design, such as longitudinal shortening[ 21 ].…”

Section: Stent Engineering Considerationsmentioning

confidence: 99%

Thin and crush: The new mantra in left main stenting?

Rigatelli¹,

Zuin²,

Dash³

2018

WJC

View full text Add to dashboard Cite

Complex bifurcations have been suggested to be better approached by a planned double stent technique; however, recent randomized trials have shown better outcomes of provisional compared to planned two-stent strategy, in terms of both short-term efficacy and safety. In left main (LM) bifurcations, double kissing (DK)-Crush has demonstrated its superiority over Culotte and provisional-T in terms of restenosis and stent thrombosis, gaining respect as one of the most performant techniques for bifurcations stenting. On the other hand, the Nano-Crush technique has recently become part of the repertoire of double stenting techniques, providing evidence that the use of ultrathin strut stents and very minimal crush would be beneficial for both the physiological and rheological properties of the complex bifurcations, even in LM scenario, leading to a lower rate of thrombosis and restenosis at both side branch and true carina. Finally, the newest generation of ultrathin strut stents are gaining a reputation for its safe and effective use in LM treatment thanks to improved design with increased expansion rate capable of LM treatment up to 5-6 mm diameter. The modern crush techniques, such as DK-Crush and Nano-Crush, are providing excellent results on mid and long-term follow up, suggesting that minimal crushing obtained using ultra-thin stents is a good way to obtain surgical-like outcomes in the treatment of complex LM bifurcation disease.

show abstract

Three‐months optical coherence tomography analysis of a biodegradable polymer, sirolimus‐eluting stent

Abstract: The Orsiro® sirolimus-eluting stent with biodegradable polymer shows early vascular healing with a high rate of strut coverage at 3-month follow-up. OCT guided stent implantation had a positive impact on early vascular healing.

Cited by 9 publications

References 23 publications

Coronary stent technology and the role of inflammation in the atherogenesis: problems and prospects

Coronary stent technology and the role of inflammation in the atherogenesis: problems and prospects

Initial Experience With the Next-Generation Resolute Onyx Zotarolimus-Eluting Stent in Symptomatic Intracranial Atherosclerotic Disease

Thin and crush: The new mantra in left main stenting?

Contact Info

Product

Resources

About